Fulfilling the Promise of RNA Therapies for Cardiac Repair and Regeneration.
Mauro GiaccaPublished in: Stem cells translational medicine (2023)
The progressive appreciation that multiple types of RNAs regulate virtually all aspects of tissue function and the availability of effective tools to deliver RNAs in vivo now offers unprecedented possibilities for obtaining RNA-based therapeutics. For the heart, RNA therapies can be developed that stimulate endogenous repair after cardiac damage. Applications in this area include acute cardioprotection after ischemia or cancer chemotherapy, therapeutic angiogenesis to promote new blood vessel formation, regeneration to form new cardiac mass, and editing of mutations to cure inherited cardiac disease. While the potential of RNA therapeutics for all these conditions is exciting, the field is still in its infancy. A number of roadblocks need to be overcome for RNA therapies to become effective, in particular, related to the problem of delivering RNA medicines into the cells and targeting them specifically to the heart.
Keyphrases
- left ventricular
- stem cells
- heart failure
- nucleic acid
- small molecule
- crispr cas
- induced apoptosis
- squamous cell carcinoma
- endothelial cells
- liver failure
- radiation therapy
- papillary thyroid
- young adults
- locally advanced
- climate change
- signaling pathway
- acute respiratory distress syndrome
- cell cycle arrest
- rectal cancer
- lymph node metastasis
- endoplasmic reticulum stress